Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
The current price of Amgen in the market is 1193,62 zł, with a 24-hour trading volume of 3,15B zł. The asset's market cap is 644,83B zł, after moving -0.31% in the last day.
Tokenized Amgen is trading at 1195,38 zł, with a tokenized market cap of 88,01K zł and a 24-hour trading volume of 3,11M zł. The tokenized asset has moved 0.68% in the past 24 hours.